| Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis MS von Itzstein, S Khan, DE Gerber Clinical chemistry 66 (6), 779-793, 2020 | 99 | 2020 |
| Association between immune-related adverse event timing and treatment outcomes D Hsiehchen, AR Naqash, M Espinoza, MS Von Itzstein, A Cortellini, ... Oncoimmunology 11 (1), 2017162, 2022 | 44 | 2022 |
| Strategies to maximize influenza vaccine impact in older adults JA Whitaker, MS von Itzstein, GA Poland Vaccine 36 (40), 5940-5948, 2018 | 28 | 2018 |
| Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors M Ahmed, MS Von Itzstein, T Sheffield, S Khan, F Fattah, JY Park, V Popat, ... Journal for ImmunoTherapy of Cancer 9 (6), 2021 | 22 | 2021 |
| Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors MS von Itzstein, AS Gonugunta, Y Wang, T Sheffield, R Lu, S Ali, FJ Fattah, ... Cancer Immunology, Immunotherapy 71 (9), 2169-2181, 2022 | 21 | 2022 |
| Application of information technology to clinical trial evaluation and enrollment: a review MS Von Itzstein, M Hullings, H Mayo, MS Beg, EL Williams, DE Gerber JAMA oncology 7 (10), 1559-1566, 2021 | 21 | 2021 |
| Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon S Khan, MS von Itzstein, R Lu, BL Bermas, DR Karp, SA Khan, FJ Fattah, ... The Oncologist 25 (5), e753-e757, 2020 | 20 | 2020 |
| Type and case volume of health care facility influences survival and surgery selection in cases with early‐stage non–small cell lung cancer S Wang, S Lai, MS von Itzstein, L Yang, DM Yang, X Zhan, G Xiao, ... Cancer 125 (23), 4252-4259, 2019 | 20 | 2019 |
| Immunotherapy use in patients with lung cancer and comorbidities MS Von Itzstein, AS Gonugunta, HG Mayo, JD Minna, DE Gerber The Cancer Journal 26 (6), 525-536, 2020 | 16 | 2020 |
| Association between antibiotic exposure and systemic immune parameters in cancer patients receiving checkpoint inhibitor therapy MS von Itzstein, AS Gonugunta, T Sheffield, J Homsi, JE Dowell, AY Koh, ... Cancers 14 (5), 1327, 2022 | 12 | 2022 |
| Humoral and cellular correlates of a novel immune-related adverse event and its treatment AS Gonugunta, MS Von Itzstein, H Mu-Mosley, F Fattah, JD Farrar, ... Journal for Immunotherapy of Cancer 9 (12), 2021 | 12 | 2021 |
| Closing the gap: Contribution of surgical best practices to outcome differences between high‐and low‐volume centers for lung cancer resection MS von Itzstein, R Lu, KH Kernstine, EA Halm, S Wang, Y Xie, DE Gerber Cancer Medicine 9 (12), 4137-4147, 2020 | 12 | 2020 |
| Statin Intolerance, Anti‐HMGCR Antibodies, and Immune Checkpoint Inhibitor‐Associated Myositis: A “Two‐Hit” Autoimmune Toxicity or Clinical Predisposition? MS von Itzstein, S Khan, V Popat, R Lu, SA Khan, FJ Fattah, JY Park, ... The oncologist 25 (8), e1242-e1245, 2020 | 11 | 2020 |
| Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study. RJ Moor, KE Roberts, R Mason, B Gunawan, S Feng, JH Hong, ... Journal of Clinical Oncology 36 (15_suppl), 9067-9067, 2018 | 10 | 2018 |
| Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report AS Gonugunta, MS von Itzstein, DE Gerber Journal of Medical Case Reports 16 (1), 289, 2022 | 9 | 2022 |
| Increasing numbers and reported adverse events in patients with lung cancer undergoing inpatient lung biopsies: a population-based analysis MS von Itzstein, A Gupta, KC Mara, S Khanna, DE Gerber Lung 197, 593-599, 2019 | 9 | 2019 |
| Severe destructive nasopharyngeal granulomatosis with polyangiitis with superimposed skull base Pseudomonas aeruginosa osteomyelitis MS Von Itzstein, JP Abeykoon, DD Summerfield, JA Whitaker Case Reports 2017, bcr-2017-220135, 2017 | 9 | 2017 |
| Systemic and intracranial efficacy of osimertinib in EGFR L747P-mutant NSCLC: case report DE Gerber, M Mayer, J Gagan, MS von Itzstein JTO Clinical and Research Reports 3 (3), 100291, 2022 | 7 | 2022 |
| Targeting TAM to tame pancreatic cancer MS von Itzstein, MC Burke, RA Brekken, TA Aguilera, HJ Zeh, MS Beg Targeted oncology 15, 579-588, 2020 | 7 | 2020 |
| Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology MS von Itzstein, E Railey, ML Smith, CB White, GW Sledge Jr, JR Howell, ... Cancer 126 (8), 1605-1613, 2020 | 7 | 2020 |
